Last reviewed · How we verify

Hyperoncotic Albumin 20%

Insel Gruppe AG, University Hospital Bern · FDA-approved active Small molecule

Hyperoncotic Albumin 20% is a Colloid volume expander Small molecule drug developed by Insel Gruppe AG, University Hospital Bern. It is currently FDA-approved for Hypovolemic shock and acute blood loss requiring rapid volume expansion, Severe hypoalbuminemia with significant fluid shifts, Perioperative volume management in major surgery. Also known as: Albumin 20%.

Hyperoncotic albumin 20% increases plasma oncotic pressure to draw fluid from interstitial spaces into the intravascular compartment, expanding blood volume and improving tissue perfusion.

Hyperoncotic albumin 20% increases plasma oncotic pressure to draw fluid from interstitial spaces into the intravascular compartment, expanding blood volume and improving tissue perfusion. Used for Hypovolemic shock and acute blood loss requiring rapid volume expansion, Severe hypoalbuminemia with significant fluid shifts, Perioperative volume management in major surgery.

At a glance

Generic nameHyperoncotic Albumin 20%
Also known asAlbumin 20%
SponsorInsel Gruppe AG, University Hospital Bern
Drug classColloid volume expander
ModalitySmall molecule
Therapeutic areaCritical Care / Acute Medicine
PhaseFDA-approved

Mechanism of action

Albumin is a natural plasma protein that acts as a colloid, exerting oncotic pressure that pulls fluid from the extravascular space into the bloodstream. The 20% concentration provides a hyperoncotic solution (higher albumin concentration than normal plasma), making it particularly effective for rapid intravascular volume expansion. This is used in acute settings where fluid shifts or hypovolemia require rapid restoration of circulating volume and hemodynamic stability.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hyperoncotic Albumin 20%

What is Hyperoncotic Albumin 20%?

Hyperoncotic Albumin 20% is a Colloid volume expander drug developed by Insel Gruppe AG, University Hospital Bern, indicated for Hypovolemic shock and acute blood loss requiring rapid volume expansion, Severe hypoalbuminemia with significant fluid shifts, Perioperative volume management in major surgery.

How does Hyperoncotic Albumin 20% work?

Hyperoncotic albumin 20% increases plasma oncotic pressure to draw fluid from interstitial spaces into the intravascular compartment, expanding blood volume and improving tissue perfusion.

What is Hyperoncotic Albumin 20% used for?

Hyperoncotic Albumin 20% is indicated for Hypovolemic shock and acute blood loss requiring rapid volume expansion, Severe hypoalbuminemia with significant fluid shifts, Perioperative volume management in major surgery.

Who makes Hyperoncotic Albumin 20%?

Hyperoncotic Albumin 20% is developed and marketed by Insel Gruppe AG, University Hospital Bern (see full Insel Gruppe AG, University Hospital Bern pipeline at /company/insel-gruppe-ag-university-hospital-bern).

Is Hyperoncotic Albumin 20% also known as anything else?

Hyperoncotic Albumin 20% is also known as Albumin 20%.

What drug class is Hyperoncotic Albumin 20% in?

Hyperoncotic Albumin 20% belongs to the Colloid volume expander class. See all Colloid volume expander drugs at /class/colloid-volume-expander.

What development phase is Hyperoncotic Albumin 20% in?

Hyperoncotic Albumin 20% is FDA-approved (marketed).

What are the side effects of Hyperoncotic Albumin 20%?

Common side effects of Hyperoncotic Albumin 20% include Hypervolemia / fluid overload, Pulmonary edema, Allergic reaction, Fever, Chills.

Related